anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients eligible for neoadjuvant chemotherapy for locally advanced stage III (non-inflammatory) breast cancer or stage IIb (triple negative or Her2+) breast cancers will be approached to participate in this single arm trial. Patients with staging investigations ruling out distant disease will be approached to participate and will undergo pre-treatment image guided core biopsy and blood samples for molecular correlative studies, followed by hypofractionated radiation (delivered prone) to entire tumor with dose constraints to skin, critical organs and contralateral breast, plus a 0.5 cm PTV. As much of the tumor that can receive planned dose of 8 Gy per fraction x 3 fractions every second day, with fall off dose to 4 Gy per fraction x 3 fractions for PTV margin. Two weeks following completion of radiation, patients will undergo a second image guided core needle biopsy of tumor and blood sample. They will then begin standard neoadjuvant chemotherapy (anthracycline and taxane based), followed by a third tissue biopsy under image guidance of any residual tumor and blood sample and then standard surgery (breast conserving or lumpectomy). This will be followed by standard whole breast radiation (50 Gy in 25 fractions). Herceptin therapy and hormonal therapy will be administered as per clinical standard when indicated. Primary outcome will be measured as pathological complete response to treatment, and secondary outcomes will include toxicity, immune markers (tumor infiltrating lymphocytes, PD-1 and PD-L1 up-regulation and changes to the circulating lymphocyte counts.
Renal fibrosis is a long-term and progressively worsening condition that impacts kidney function during aging and in the context of chronic kidney disease (CKD). CKD and renal fibrosis affect approximately 10% of the global population and are prevalent in about half of individuals over the age of 70. Despite ongoing research, the mechanisms underlying renal fibrosis are still not well understood, and there is currently a lack of effective treatments available. In the present study, we demonstrated a significant increase of circPWWP2A in renal tubular cells both in vivo and in vitro models of renal fibrosis. Suppressing circPWWP2A has the potential to reduce mitochondrial dysfunction and the production of mitochondrial reactive oxygen species (mtROS), ultimately leading to the inhibition of renal fibrosis. Whereas, supplementation of circPWWP2A led to more serve mitochondrial dysfunction, mtROS production and renal fibrosis. Mechanistically, we found the expression of circPWWP2A was negatively correlated with the expression of miR-182. And we further confirmed miR-182 was the direct target of circPWWP2A by dual-luciferase reporter assay and RIP assay. Then, we found miR-182 suppressed the expression of ROCK1 in both in vitro and in vivo models of renal fibrosis. Luciferase microRNA target reporter assay further indicated ROCK1 as a direct target of miR-182. Knockdown of ROCK1 inhibits renal fibrosis and mitochondrial dysfunction, suggesting ROCK1 not only served as an injurious role in mitochondrial homeostasis but also a pro-fibrotic factor in CKD. Taking together, our findings suggest that circPWWP2A may promote renal interstitial fibrosis by modulating miR-182/ROCK1-mediated mitochondrial dysfunction.
INTRODUCTION: The increase in suicidal behavior among adolescents under 17 years of age in Catalonia between 2019 and 2022 has gone from 473 to 1425 cases, which entails a new healthcare challenge. The objective of the article is to explain the procedure and intervention of the Rapid Response Unit (RRU) for children and adolescents at risk of suicide. The RRU is a multidisciplinary unit designed to prevent relapse and increase link-up to treatment. The cases attended in its 14 months of operation are described.
METHODOLOGY: 24 patients, 18 females and 6 males aged between 12 and 17 years, attended for the first time at the Child and Adolescent Health Centre of Cornellà for activation of the Suicide Risk Code (CRS) in hospital emergency departments during the period studied.
RESULTS: After the intervention, high suicidal risk decreased from 29.17% to 0%, medium risk decreased from 37.5% to 20.83% and low risk increased from 33.33% to 79.17%. In addition, there was only one new CRS activation in the 3 months following the first activation. In the RRU, care was intensive: 52.7% of cases with visits once a week and more than once a week in 24.9%. During the intervention months 100% of cases were linked and no interruptions occurred.
CONCLUSIONS: Rapid Response Unit (RRU) decreases the risk of recurrence of suicidal behavior and ensures therapeutic linkage.
Part 1: Blood is obtained from participants with mild/moderate HF on 3 consecutive days, and participants undergo CMR and 2DSTE on one of those 3 days. Part 2: Within 5 days of completing Part 1 participants have a 24 hour loop diuretic withdrawal, and 15 hour 0.9% normal saline infusion; followed by a blood draw, CMR and 2DSTE.
This arm will receive IPT-G for 12 weeks. Following IPT-G, this arm will go on to receive the Care Group intervention parallel to the control arm.
This study aimed to utilize machine learning to explore the psychological similarities and differences between suicide attempt (SA) and non-suicidal self-injury (NSSI), with a particular focus on the role of psychological pain. A total of 2385 middle school students were recruited using cluster sampling. The random forest algorithm was used with 25 predictors to develop classification models of SA and NSSI, respectively, and to estimate the importance scores of each predictor. Based on these scores and related theories, shared risk factors (control feature set) and distinct risk factors (distinction feature set) were selected and tested to distinguish between NSSI and SA. The machine learning algorithm exhibited fair to good performance in classifying SA history [Area Under Curves (AUCs): 0.65-0.87] and poor performance in classifying NSSI history (AUC: 0.61-0.68). The distinction feature set comprised pain avoidance, family togetherness, and deviant peer affiliation, while the control feature set included pain arousal, painful feelings, and crisis events. The distinction feature set slightly but stably outperformed the control feature set in classifying SA from NSSI. The three-dimensional psychological pain model, especially pain avoidance, might play a dominant role in understanding the similarities and differences between SA and NSSI.
YONSA may cause hypertension, hypokalemia, and fluid retention as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition [see Clinical Pharmacology (12.1)]. Monitor patients for hypertension, hypokalemia, and fluid retention at least once a month. Control hypertension and correct hypokalemia before and during treatment with YONSA.

In the two randomized clinical trials, grade 3 to 4 hypertension occurred in 2% of patients, grade 3 to 4 hypokalemia in 4% of patients, and grade 3 to 4 edema in 1% of patients treated with abiraterone acetate [see Adverse Reactions (6)].

Closely monitor patients whose underlying medical conditions might be compromised by increases in blood pressure, hypokalemia or fluid retention, such as those with heart failure, recent myocardial infarction, cardiovascular disease, or ventricular arrhythmia. In postmarketing experience, QT prolongation and Torsades de Pointes have been observed in patients who develop hypokalemia while taking abiraterone acetate.

The safety of YONSA in patients with left ventricular ejection fraction < 50% or New York Heart Association (NYHA) Class III or IV heart failure (in Study 1) or NYHA Class II to IV heart failure (in Study 2) has not been established because these patients were excluded from these randomized clinical trials [see Clinical Studies (14)].
<P>PROBLEM TO BE SOLVED: To obtain a composition for treating or preventing chapped skin, having an excellent treatment or prevention effect on chapped skin.  <P>SOLUTION: The composition for treating or preventing chapped skin comprises chondroitin sulfate, hyaluronic acid and a II type collagen as active ingredients. The chondroitin sulfate, hyaluronic acid and II type collagen are a complex extracted from salmon cartilage. The composition is formulated so as to daily have 10mg-5g total of the chondroitin sulfate, hyaluronic acid and II type collagen. The food comprises chondroitin sulfate, hyaluronic acid and II type collagen as active ingredient. The composition is used for at least one of enhancement of moisture retention power of skin, amelioration of water transpiration amount of skin, amelioration of texture of skin and amelioration of skin wrinkles.  <P>COPYRIGHT: (C)2007,JPO&INPIT
An embodiment of an analyte detection system includes a fluid transport network having a patient end configured to provide fluid communication with a body fluid in a patient and a body fluid analyzer accessible via the fluid transport network. The body fluid analyzer is configured to determine a level of an analyte of interest. A pump unit is coupled to the fluid transport network and has a sample input mode and an infusion mode. In the sample input mode, the pump unit is operable to transport a sample of the body fluid from the patient end and toward the body fluid analyzer. In the infusion mode, the pump unit is operable to transport an infusion fluid toward and out the patient end. The analyte detection system also includes a user interface for communication with the body fluid analyzer. The user interface includes a trend display portion that includes a trend indicator, which depicts a trend in determined levels of the analyte of interest. The trend display portion also includes at least one of a high-level indicator corresponding to a relatively high level of the analyte and a low-level indicator corresponding to a relatively low level of the analyte.
Probes were placed in the sham laser group in a similar way as in the treatment group. The screen of the laser device was active; however, the energy was set as 0 J and the power as 0 mW , respectively,and the same operations were also performed.
Participants will be instructed on the task which they will perform at home online using a keyboard. The training involved auditory-cued audiovisual finger movement sequence learning task. Participants will complete an online computer-based training of 20 minutes at home 3 times per week for the duration of 8 weeks, and a total of 24 sessions, the duration and number of sessions.
PURPOSE:To obtain the titled aqueous preparation stably maintaining allantoin for a long period, showing high treating effects, by blending an allantoin- containing aqueous preparation with an organic acid, inorganic acid, amino acid or an alkali metallic salt thereof as a stabilizer. CONSTITUTION:An allantoin-containing aqueous preparation is blended with 0.01-20wt% organic acid (e.g. citric acid, tartaric acid or succinic acid), inorganic acid (e.g. phosphoric acid, polyphosphoric acid or hydrochloric acid), amino acid (e.g. glutamic acid, aspartic acid or glycine) or alkaline metallic salt thereof as a stabilizer. In the preparation, allantoin partially exists in a dissolved state and the preparation exhibits higher treating effects on ulcer, wound, decubitus, congelation and burn than an ointment or powder using an existing oily base.
Dose-escalation stage to identify the MTD and the RP2D, defined as either the MTD or a dose below the MTD that the Data and Safety Review Committee (DSRC) agree shows adequate pharmacological evidence of target engagement and/or clinical activity. Subjects will receive ASTX660 once a day for 7 consecutive days every other week of each 28-day cycle (ie, \[7 days on/ 7 days off\] ×2; daily dosing on Days 1-7 and 15-21). The starting dose will be escalated stepwise in successive cohorts of 3 to 6 evaluable subjects each (standard 3+3 study design), until the RP2D is determined.
Non-communicable diseases (NCDs) are the pandemics of modern era and are generating huge impact in the modern society. Conventional methods are inaccurate due to a challenge in handling data from heterogenous sensors. The present disclosure is capable of tracking fitness parameters of a user even with heterogenous sensors. Initially, the system receives a raw data from a plurality of heterogenous sensors associated with the user. The raw data is further transformed into a metadata format associated with the corresponding sensor. The transformed data is temporally aligned based on a time based slotting. An algorithm pipeline corresponding to a disorder to be analyzed is selected from a Directed Acyclic Graph (DAG) based on a sensor metadata and a plurality of algorithm metadata corresponding to a plurality of algorithms stored in an algorithm database and an algorithm pipeline. The corresponding disorder is analyzed using the algorithm pipeline.
The invention provides a wild kiwi fruit/onion health-preserving wine and a preparation method thereof. Onion juice with lower acidity is added into the wild kiwi fruit unblended wine, thereby effectively lowering the overall acidity of the finished wine. Besides, the onions have favorable piquancy, so the wine has richer mouthfeel and longer aftertaste. The onions have the advantages of lower market price, high storability and high juice yield, so the product cost is greatly lowered. The onion juice is added at the time of semifinished wine fining, thereby maintaining the natural color of the onions, and avoiding the loss of nutrients and flavor in the fermentation process. The onion juice participates in the semifinished product cold-treating process, thereby enhancing the non-biological stability of the finished wine. The onion juice can enhance the health-care effect of the wild kiwi fruit wine; allyl disulfides and small mounts of sulfur amino acids contained in the onion juice have the function of lowering blood pressure; and the allyl disulfides and sulfur amino acids belong to glycosides, have the effect of resisting artery blood vessels from hardening, and can prevent thrombosis from formation; and sulfoureido butyric acid contained in the onions can obviously lower the blood sugar content.
<P>PROBLEM TO BE SOLVED: To provide a novel backbone-cyclized analog comprising a peptide sequence containing at least two building units.  <P>SOLUTION: The backbone-cyclized peptide analog is formed by means of bridging groups bonded via the alpha nitrogen atoms of an amino acid derivative to provide novel nonpeptidic linkages. The novel building units are N<SP>α</SP>/(ω-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N<SP>α</SP>/(ω-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The peptide analog is exemplified by a backbone-cyclized bradykinin antagonist having biological activity. A further embodiment is somatostatin analog having one or two ring structures involving main chain cyclization.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Pre-hospital emergency care is a very important part of Emergency Medical Service (EMS) System, crucial to patients' life support, disability and mortality rate reduction. The level of pre-hospital emergency care reflects the comprehensive ability of the organizational, management and public welfare of a country. Beijing Emergency Center and Beijing Red Cross Emergency Center are in the charge of all the pre-hospital emergency care in Beijing, which respectively subordinate to Beijing government and Chinese Red Cross Society. This study collected the data of 3,909,746 cases from these two pre-hospital care centers from January, 2005 to December, 2014 and retrospective analyzed the pre-hospital emergency call demand and first aid related time. The results of this study can help the government optimize medical resources; strengthen the prevention of related emergency diseases. The changes and trends of pre-hospital care disease spectrum also present the same problems and situation of developing megacities like Beijing. Based on the meticulous work in these 2 centers, this study has collected the most complete pre-hospital emergency care data in China.
The invention provides a traditional Chinese medicine product suitable for improving male immunity. The product comprises the following 18 raw materials: Chinese yarn, hawthorn, eucommia ulmoides, radix polygoni multiflori, medlar, prepared rehmannia glutinosa, radix astragali, black bean, radix ginseng, fructus schisandrae, morinda officinalis, mulberry fruit, semen cuscutae, herba cistanchis, bitter squash, herba portulacae, turnip and sliced rhizoma zingiberis. The invention also provides a method for preparing the traditional Chinese medicine product. The traditional Chinese medicine product is suitable for people who are physically weak and sickly, has limb myasthenia and poor immunity, is liable to catch a cold, and is prematurely senile with the syndrome of kidney-yang insufficiency. The traditional Chinese medicine product is also particularly effective for the survivors who take poisons. The traditional Chinese medicine product is taken to effectively improve the immunity, prevent influenza, slow down the cell aging process and prolong the life, and has the efficacies of consolidating the constitution, replenishing the essence, tonifying the kidney-yang and repelling toxic substances. The raw materials of the product are easily available and low in price, and the product is suitable for common people to achieve the purposes of routine health care, disease prevention, physical fitness and life prolonging.
The invention provides a biological fermentation primary liquid mask and a preparation method and a storing method thereof and belongs to the field of cosmetics. The biological fermentation primary liquid mask is free of a carrier, is attached to the face and free of washing. The biological fermentation primary liquid mask is formed in the mode that blueberries, ginseng, roses, chamomile, soybean and tremella are decocted and fermented. The preparation method comprises the following steps that raw materials are screened, weighed and cleaned in sequence and then mixed, water is added, decocting is conducted, cooling and filtering are conducted, a product is poured into a mould containing original fungi, and then fermentation is conducted for 5-7 days at the temperature of 30-32 DEG C with the humidity being 40%-45% in an air atmosphere; in this way, the biological fermentation primary liquid mask is obtained, wherein the pH value is about 6.8. The storing method of the biological fermentation primary liquid mask comprises the steps that the mask is stored in storage liquid, sealed in vacuum and then stored in a shady, cool and dry place, wherein the storing liquid comprises lemon hydrosol, tea tree hydrosol, lavender hydrosol and mycose. The biological fermentation primary liquid mask achieves the purposes of whitening skin, removing beverage, redness, acne and wrinkles, shrinking pores, eliminating fat granules, improving dark and dry skin, removing dead skin and the like at a time.
OBJECTIVE: To analyze the risk factors affecting psychiatric behavior and study the psychobehavioral conditions of children with epilepsy.
METHOD: We randomly selected and enrolled 294 children with epilepsy who visited and were hospitalized in the pediatric clinic of Hebei General Hospital between January 2017 and January 2022, as the study participants. We comprehensively assessed their cognitive functions using the Gesell development schedule or Wechsler Intelligence Scales. The participants were divided into the study group (n = 123) with cognitive impairment and the control group (n = 171) with normal cognitive functions, for analysis.
RESULTS: There were statistically significant differences between the two groups in disease course, frequency of epilepsy, status epilepticus, and the number of antiseizure medications (ASMs) used (P < 0.05), while there were no statistically significant differences in age, gender, age of onset, form of onset, interictal epileptiform discharge, history of febrile convulsion, and the time from onset to initial visit (P > 0.05). Based on multivariate logistic regression analysis, the course of disease, frequency of onset, status epilepticus and number of ASMs used were identified as high-risk factors for cognitive impairment in children with epilepsy. Similarly, early onset, long course of disease, known etiology, and combination of multiple drugs have a negative impact on behavioral problems, school education, and social adaptability.
CONCLUSION: The course of disease, the frequency of onset, status epilepticus, and the number of ASMs used are high-risk factors for cognitive impairment in children with epilepsy, which can be prevented and controlled early. When selecting ASMs, their advantages and disadvantages should be weighed. Moreover, the availability of alternative treatment options must be considered. With the help of genomic technology, the causes of epilepsy should be identified as early as possible, and precision medicine and gene therapy for children with epilepsy should be actively developed.
The identification of a safe, effective treatment for individuals with early mild-to-moderate symptomatic COVID-19 that prevent progression to more severe disease would have immediate public health implications. A hallmark of severe COVID-19 disease is immune system dysregulation called cytokine storm. Multiple studies have reported that patients with severe disease demonstrate elevated levels of pro-inflammatory cytokines early in disease, and elevated IL-6 plasma concentrations are predictive of poor clinical outcomes in COVID-19. Disulfiram, an FDA-approved drug for the treatment of alcohol dependence disorder is an appealing therapeutic option for COVID-19. It has a good safety profile, easy dosing schedule, and recent data suggesting multiple mechanisms by which disulfiram may act on COVID-19 (both as a direct antiviral agent as well as indirect effects on reducing inflammation). In addition disulfiram has been studied extensively with detailed available pharmacokinetic data; disulfiram has a short half-life \~7.5 hours with \>90% of drug eliminated within 3 days post-dose, allowing quick reversal of any potential adverse effects. We will perform a phase 2 randomized (2:1), double blind placebo-controlled assessment of disulfiram in people with early mild-to-moderate symptomatic COVID-19. A total of 60 symptomatic COVID+ individuals will enrolled to receive active drug versus placebo (with equal distribution of mild or moderate/severe within each dosing cohort and within each randomization arm). For cohort 1, N=20 will receive DSF 1000 mg/N=10 placebo, and for cohort 2, N=20 will receive DSF 2000 mg/N=10 placebo. Drug/placebo will be administered using strict infection control protocols designed to support the study of people with acute COVID-19 infection per the Center for Diseases Control (CDC) guidelines (https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-in-home-patients.html).
This is a randomized, double-blind, clinical trial, comparing the association of Chlorthalidone plus amiloride 25 and 5 mg daily, versus amlodipine 10 mg daily as first drug option in patients older than 40 years of age with Stage I hypertension (140-159/90-99 mmHg) and moderate obstructive sleep apnea (15-30 apneas/hour of sleep). The primary outcomes will be the variation of apneas/hour and blood pressure. The secondary outcomes will be adverse events, somnolence scale (Epworth), ventilatory parameters and C reactive protein. The follow up will last 8 weeks. The sample size will be of 29 participants per group. The project was approved by the Ethics committee of our institution.